Standard

A microfluidic platform for the characterisation of membrane active antimicrobials. / Al Nahas, K.; Cama, J.; Schaich, M.; Hammond, K.; Deshpande, S.; Dekker, C.; Ryadnov, M. G.; Keyser, U. F.

In: Lab on a Chip, Vol. 19, No. 5, 2019, p. 837-844.

Research output: Contribution to journalArticleScientificpeer-review

Harvard

Al Nahas, K, Cama, J, Schaich, M, Hammond, K, Deshpande, S, Dekker, C, Ryadnov, MG & Keyser, UF 2019, 'A microfluidic platform for the characterisation of membrane active antimicrobials' Lab on a Chip, vol. 19, no. 5, pp. 837-844. https://doi.org/10.1039/c8lc00932e

APA

Al Nahas, K., Cama, J., Schaich, M., Hammond, K., Deshpande, S., Dekker, C., ... Keyser, U. F. (2019). A microfluidic platform for the characterisation of membrane active antimicrobials. Lab on a Chip, 19(5), 837-844. https://doi.org/10.1039/c8lc00932e

Vancouver

Author

Al Nahas, K. ; Cama, J. ; Schaich, M. ; Hammond, K. ; Deshpande, S. ; Dekker, C. ; Ryadnov, M. G. ; Keyser, U. F. / A microfluidic platform for the characterisation of membrane active antimicrobials. In: Lab on a Chip. 2019 ; Vol. 19, No. 5. pp. 837-844.

BibTeX

@article{285a1cd4c08441b38ed11b1dc7449278,
title = "A microfluidic platform for the characterisation of membrane active antimicrobials",
abstract = "The spread of bacterial resistance against conventional antibiotics generates a great need for the discovery of novel antimicrobials. Polypeptide antibiotics constitute a promising class of antimicrobial agents that favour attack on bacterial membranes. However, efficient measurement platforms for evaluating their mechanisms of action in a systematic manner are lacking. Here we report an integrated lab-on-a-chip multilayer microfluidic platform to quantify the membranolytic efficacy of such antibiotics. The platform is a biomimetic vesicle-based screening assay, which generates giant unilamellar vesicles (GUVs) in physiologically relevant buffers on demand. Hundreds of these GUVs are individually immobilised downstream in physical traps connected to separate perfusion inlets that facilitate controlled antibiotic delivery. Antibiotic efficacy is expressed as a function of the time needed for an encapsulated dye to leak out of the GUVs as a result of antibiotic treatment. This proof-of-principle study probes the dose response of an archetypal polypeptide antibiotic cecropin B on GUVs mimicking bacterial membranes. The results of the study provide a foundation for engineering quantitative, high-throughput microfluidics devices for screening antibiotics.",
author = "{Al Nahas}, K. and J. Cama and M. Schaich and K. Hammond and S. Deshpande and C. Dekker and Ryadnov, {M. G.} and Keyser, {U. F.}",
year = "2019",
doi = "10.1039/c8lc00932e",
language = "English",
volume = "19",
pages = "837--844",
journal = "Lab On a Chip: microfluidic and nanotechnologies for chemistry, biology, and bioengineering",
issn = "1473-0197",
publisher = "Royal Society of Chemistry",
number = "5",

}

RIS

TY - JOUR

T1 - A microfluidic platform for the characterisation of membrane active antimicrobials

AU - Al Nahas, K.

AU - Cama, J.

AU - Schaich, M.

AU - Hammond, K.

AU - Deshpande, S.

AU - Dekker, C.

AU - Ryadnov, M. G.

AU - Keyser, U. F.

PY - 2019

Y1 - 2019

N2 - The spread of bacterial resistance against conventional antibiotics generates a great need for the discovery of novel antimicrobials. Polypeptide antibiotics constitute a promising class of antimicrobial agents that favour attack on bacterial membranes. However, efficient measurement platforms for evaluating their mechanisms of action in a systematic manner are lacking. Here we report an integrated lab-on-a-chip multilayer microfluidic platform to quantify the membranolytic efficacy of such antibiotics. The platform is a biomimetic vesicle-based screening assay, which generates giant unilamellar vesicles (GUVs) in physiologically relevant buffers on demand. Hundreds of these GUVs are individually immobilised downstream in physical traps connected to separate perfusion inlets that facilitate controlled antibiotic delivery. Antibiotic efficacy is expressed as a function of the time needed for an encapsulated dye to leak out of the GUVs as a result of antibiotic treatment. This proof-of-principle study probes the dose response of an archetypal polypeptide antibiotic cecropin B on GUVs mimicking bacterial membranes. The results of the study provide a foundation for engineering quantitative, high-throughput microfluidics devices for screening antibiotics.

AB - The spread of bacterial resistance against conventional antibiotics generates a great need for the discovery of novel antimicrobials. Polypeptide antibiotics constitute a promising class of antimicrobial agents that favour attack on bacterial membranes. However, efficient measurement platforms for evaluating their mechanisms of action in a systematic manner are lacking. Here we report an integrated lab-on-a-chip multilayer microfluidic platform to quantify the membranolytic efficacy of such antibiotics. The platform is a biomimetic vesicle-based screening assay, which generates giant unilamellar vesicles (GUVs) in physiologically relevant buffers on demand. Hundreds of these GUVs are individually immobilised downstream in physical traps connected to separate perfusion inlets that facilitate controlled antibiotic delivery. Antibiotic efficacy is expressed as a function of the time needed for an encapsulated dye to leak out of the GUVs as a result of antibiotic treatment. This proof-of-principle study probes the dose response of an archetypal polypeptide antibiotic cecropin B on GUVs mimicking bacterial membranes. The results of the study provide a foundation for engineering quantitative, high-throughput microfluidics devices for screening antibiotics.

UR - http://www.scopus.com/inward/record.url?scp=85062173659&partnerID=8YFLogxK

U2 - 10.1039/c8lc00932e

DO - 10.1039/c8lc00932e

M3 - Article

VL - 19

SP - 837

EP - 844

JO - Lab On a Chip: microfluidic and nanotechnologies for chemistry, biology, and bioengineering

T2 - Lab On a Chip: microfluidic and nanotechnologies for chemistry, biology, and bioengineering

JF - Lab On a Chip: microfluidic and nanotechnologies for chemistry, biology, and bioengineering

SN - 1473-0197

IS - 5

ER -

ID: 51999322